PreCardix® Professional Resources

Recommend PreCardix® with Confidence.

Welcome to PreCardix® Professional Resources. This section provides important information for health care providers on prescribing PreCardix® to patients. Content on this page has been peer-reviewed through third-party health care providers or internally by our Medical Advisory Board. Hypertension Canada has reviewed content on this site in compliance with their Proud Supporter Program. If you have any additional questions about PreCardix®, please contact us directly at


Clinical Research

PreCardix® is the result of over a decade research and development dedicated to finding an effective, sustainable and proven natural product to support blood pressure health.

Two clinical studies, Mare-study (preliminary clinical trial) and Marealis 13TBHM (peer-reviewed, double-blind, placebo-controlled, multicentre clinical trial), were conducted on the bioactive marine peptides (RSPC) in PreCardix® between 2012 and 2015 on over two hundred and twenty male and female participants aged 30 – 75.

Clinical research found that the unique bioactive marine peptides derived from hydrolyzed shrimp shells (Pandalus Borealis) found in PreCardix® have an ACE inhibiting action. The use of bioactive marine peptides in clinical trials resulted in a statistically significant effect blood on pressure health in over 89% of participants within eight weeks or less.

Highlights of the Marealis 13TBHM study:

  • 1,200 mg per day of unique bioactive marine peptides have a statistically significant effect blood on pressure health in adults with mild to moderate hypertension
  • Angiotensin II levels were significantly reduced in the treatment group compared to baseline documenting the ACE-inhibiting action
  • No significant side effects were experienced by study participants, including hypotension, angioedema, dry cough, or hyperkalemia
  • 89% of clinical trial participants experienced a significant effect on blood pressure health within eight weeks or less
  • 43% of clinical trial participants experienced a change in blood pressure by over 10mmHg in eight weeks
  • 24% of clinical trial participants experienced a change in blood pressure by over 15mmHg within eight weeks

For more information on PreCardix® clinical indications, safety and effectiveness, please review the resources below, including clinical research, product monographs, and FAQs.

Important Information

PreCardix® does not treat, cure or prevent blood pressure-related conditions. Measure and monitor blood pressure regularly. Know the signs of heart attack and stroke. Do not take PreCardix® if you are pregnant, breastfeeding, have renal artery stenosis, history of angioneurotic edema, or shellfish allergy. Always consult with your health care provider before making changes to your blood pressure management plan.






Hypertension Canada